Research Growth at NCRC
Colin Duckett, PhD, Director of NCRC Program Development, speaks on important new research.
In a recent interview with annarbor.com, Colin Duckett, PhD, director of program development at NCRC shared his optimism about one of the several research programs being developed at NCRC - research to benefit patients facing cancer. Moving his own lab to NCRC this month, he is excited about the new Translational Oncology Program at NCRC, led by Diane Simeone, MD. Under the umbrella of this program, medical researchers, biologists, chemists, pharmacologists and engineers have begun to co-locate to NCRC to tackle some of the most pressing challenges facing cancer researchers. Their co-existence under one roof - certainly unusual at the university, will allow them unprecedented opportunities to collaborate on research.
A key goal of the Translational Oncology Program is to speed up the process of development of new therapies that can quickly move from the research labs to clinics in order to help the patients. NCRC is unique in being able to provide state-of-the-art labs and much-needed space to bring together inter-disciplinary researchers to work on such research.
While space is a fantastic resource that NCRC provides to further the university's research enterprise, the thoughtful and planned investment decisions by the NCRC leadership in developing strategic research programs is also a key factor.
Ultimately, the measure of the success of the program will be in reaching patients with cancer and making breakthrough treatments available to them. In his interview, Dr. Duckett said, "It may be, though, that the person who is cured by a novel treatment developed by a Michigan-based researcher, or a multinational team that includes scientists from U-M, may never visit Michigan or even know what NCRC is. And that's fine."
In providing research space as well as the vision to nurture translational research, NCRC plays a critical role in this process.